CN105998697A - Medicine composition for treating esophagus cancer - Google Patents

Medicine composition for treating esophagus cancer Download PDF

Info

Publication number
CN105998697A
CN105998697A CN201610501397.1A CN201610501397A CN105998697A CN 105998697 A CN105998697 A CN 105998697A CN 201610501397 A CN201610501397 A CN 201610501397A CN 105998697 A CN105998697 A CN 105998697A
Authority
CN
China
Prior art keywords
ethanol
weight portion
herba
pharmaceutical composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610501397.1A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610501397.1A priority Critical patent/CN105998697A/en
Publication of CN105998697A publication Critical patent/CN105998697A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine composition for treating esophagus cancer and a preparation method thereof. The medicine composition is prepared from the following medicinal raw materials: oberonia iridifolia, ivy glorybind herb root, sciadopitysin, mazus stachydifolius and adinandra mellettii in a proportion. Various preparations can be prepared from the medicine composition according to a conventional preparation process, and have a remarkable effect for treating esophagus cancer.

Description

A kind of pharmaceutical composition treating esophageal carcinoma
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition treating esophageal carcinoma and preparation side thereof Method.
Background technology
The esophageal carcinoma refers to betide the malignant tumor of mucous membrane of esophagus epithelium, accounts for the 2% of all malignant tumor.Site of pathological change with In esophagus, hypomere in the majority, respectively account for the esophageal carcinoma more than 40%.Swallow difficulty, regurgitation of food with Progressive symmetric erythrokeratodermia, swallow pain for mainly to face Bed feature.Person in middle and old age are susceptible to suffer from primary disease, and the morbidity of the 80% of China is after 50 years old.Male is higher than women.The whole world is the biggest There are about more than 20 ten thousand people and die from the esophageal carcinoma, China's death every year reaches more than 150,000 people, occupies the biggest portion of world's death from esophageal carcinoma number Point.China is with Taihang mountain areas, Eastern Qinling Mountain, Da Bie Mountain area, Northern Sichuan Province area, the south of Fujian Province and Chao-Shan Area, Guangdong, Soviet Union Backlands district is district occurred frequently.
Carrying out radiotherapy for advanced esophagus cancer patients is one of the most clinical essential therapeutic arsenals.Chinese medicine is because of tool There are the effects such as invigorating blood circulation tired, heat-clearing and toxic substances removing, strengthening the body resistance to play antitumor action, may act on tumorigenesis many Individual link.Chinese medicine is suppressing killing tumor cell, is improving symptom and alleviate chemicotherapy untoward reaction, extend the survival of patients phase etc. Aspect plays a significant role.But the most still lack effective medicine for the treatment of esophageal carcinoma.
Herba mazi stachydifolii: this product is Scrophulariaceae Mazus plant Herba mazi stachydifolii Mazus stachydifolius (Turcz.) herb of Maxim..Gather when yielding positive results, dry.[nature and flavor] taste is micro-pungent；Cool in nature.[function cures mainly] heat clearing away solution Poison；Cool the blood dissipate blood stasis.Main constipation hematochezia；Furuncle toxic swelling；Venom；Traumatic injury.[original shape state] perennial herb, high 10- 50cm.Sturdy, Herb is by white long pubescence.Root stock is short；Stem is upright, dilute rising, cylindrical, not branch or base portion branch, always Time base portion lignifying.Basal leaf cochlear, has short handle, the most withered；Stem leaf is to life, the normal alternate on top, stockless；Blade length is oval Shape is to the shape of falling ovum lanceolar；Papery, long 2-7cm, big with the amount in the middle part of stem, edge tool sawtooth.Raceme top is raw, long 2- 20cm, spends sparse；Bract triangle；Calyx funnel-form, long 0.5-1cm, longer than bennet, calyx tooth is slightly longer than cylinder portion, and tip length is sharp Point；Corolla is purple with, long 1.5-2cm；Tube is the most isometric with lip, and upper lip is short, and 2 split, sliver long-narrow triangular mesh, end point, under Lip is roomy, carries out, and 3 split, and middle sliver is little compared with side sliver, and subcircular is the most prominent, have two the gauffer of raw glandular hair go directly throat； 4 pieces of stamen, the last two；Ovary top is by long bristle.The flat ovoid of capsule, long 2-4mm.The month at florescence 4-6, really the phase 7-9 month.Record in Chinese medicine voluminous dictionary.
Herba Oberoniae iridifoliae: this product is the orchid family Rhizoma Iridis Tectori epidendrum Rhizoma Iridis Tectori orchid Oberonia iridifolia (Roxb.) Lindl. The herb of [Cymbidium iridifolium Roxb.].The whole year all can gather, and boiled water dries after scalding.[nature and flavor] micro-hardship；Property Cool.[return through] bladder warp.[function cures mainly] clearing away heat-damp and promoting diuresis；Promoting blood circulation to remove obstruction in the collateral.Main urinary tract infection；Bronchitis；Asthma；Enteritis； Dyspepsia；Traumatic injury；Fracture.[former phytomorph] Rhizoma Iridis Tectori is blue, perennial draft of growing nonparasitically upon another plant, high 12-30cm, bunch raw most palpuses Root.Leaf is thick, and both sides are flattened and mutual intussusception, and sword shape or long round shape lanceolar, long 4-13cm, wide 1-2cm, tip is the most askew Tiltedly, base portion has joint.Raceme is extracted out from plant center, is longer than leaf, uprightly, cylindrical, the most intensive little Hua of tool；Little The thin keratin of bract, avette, long 1.5-2mm.Spend little, diameter about 2mm, green in vain；Sepal and the equal opisthotonos of petal, petal compares sepal Narrow；Lip is the most semicircle, and shape is closely eroded at edge, and tip 2 splits.The capsule shape of falling ovum is oval, is about 5mm, the long 1.5mm of handle.Florescence The 10-11 month, really the phase 11-12 month.Record in Chinese medicine voluminous dictionary.
Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae): this product is Convolvulaceae calystegia plant DAWANHUA Calystegia hederacea Wall. The herb of [Convolvu-lus japonicus Thunb.].Summer, autumn gather, and clean, dry.[nature and flavor] sweet micro-hardship；Flat. [return through] liver；Kidney channel.[function cures mainly] spleen invigorating；Dampness removing；Regulating menstruation.Main weakness of the spleen and stomach；Dyspepsia；Infantile milk regurgitation；Infantile malnutrition；Five Drench；Leukorrhagia；Menoxenia.[character] rhizome is elongated, diameter about 1mm, surface lark, has thin vertical wrinkle.Stem is elongated, the most tortuous Turn round volume, surface taupe brown or taupe, have longitudinal crest line to distort；Matter is crisp, frangibility.Leaf alternate, has long handle, blade pale green Color, many shrinkages crush, in halberd shape after intact leaf flattening.Feeble QI is lightly seasoned.[chemical analysis] rhizome contains anti-caprolactone (columbin), palm leaf coculine (palmatine).Leaf lactoside (kaempferol-3-galacto-Han Kaempferol-half side).Record in Chinese medicine voluminous dictionary.
Adinandra millettii: this product is Theaceae Adinandra millettii platymiscium Adinandra millettii Adinandra millettii(Hook.et Arn.) The root of Benth.et Hook.f. and tender leaf.Root can be adopted the whole year, dries.Tender leaf summer, Qiu Cai, using fresh herb.[nature and flavor] are bitter；Cool.[return Warp] lung；Liver Channel.[function cures mainly] cooling blood for hemostasis；Removing toxic substances and promoting subsidence of swelling.Main epistaxis；Hematuria；Infectious hepatitis；Parotitis；Furuncle and phyma；Serpentis Insect bite is hindered；Cancerous protuberance.[former phytomorph] Adinandra millettii shrub or dungarunga, high about 5m.Twig and terminal bud dredge raw pubescence.Single leaf is mutual Raw；Leaf tool short handle；Blade heavy leather matter, long round shape is oval, and long 4.5-9cm, wide 2-3cm, the short point of tip, base portion is the narrowest, edge Quan Yuan, rare at the first half slightly denticulation, there is intensive pubescence during children, become without hair afterwards.Flower both sexes, are singly born in axil；Bennet Very thin, it is about 2cm, has patch volt undercoat, sepal 5, ovum shape triangle, outside pasted volt undercoat, and edge is bordering on film quality, has thin gland tooth And eyelashes；Corolla lobe 5, without hair；About 25 pieces of stamen, the close raw white pubescence of flower pesticide；Ovary is upper, Room 3, has white pubescence, flower Post is without hair.Berry is subsphaeroidal, diameter 7-8mm, has pubescence or is bordering on without hair.Seed is tiny, black, light.Record in Chinese medicine big Dictionary.
7,4',4'''-Trimethylamentoflavone (Sciadopitysin): CAS 521-34-6, molecular weight 580.53766, molecular formula C33H24O10, fusing point 296-298 DEG C.[ingredient origin] Semen Ginkgo Ginkgo biloba, Folium et Ramulus Cephalotaxi Cephalotaxus Fortunei, Ramulus et folium taxi cuspidatae Taxus cuspidata.
1 crude drug chemical constitution:
7,4',4'''-Trimethylamentoflavone (Sciadopitysin).
Summary of the invention
It is an object of the invention to overcome the deficiency of background technology, it is provided that the pharmaceutical composition of a kind of effective treatment esophageal carcinoma and Its preparation method.
The present invention adopts the following technical scheme that realization:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment esophageal carcinoma be:
Herba Oberoniae iridifoliae 120-160 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 80-100 weight portion 7,4',4'''-Trimethylamentoflavone 20-30 weight portion Herba mazi stachydifolii 60- 80 weight portion Adinandra millettii 40-70 weight portions.
It is preferably used in the pharmaceutical composition for the treatment of esophageal carcinoma, is made up of the crude drug of following weight portion:
Herba Oberoniae iridifoliae 140 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 90 weight portion 7,4',4'''-Trimethylamentoflavone 25 weight portion Herba mazi stachydifolii 70 weight portion Adinandra millettii 50 weight portions.
A kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that pharmaceutical composition can use the routine side of galenic pharmacy Method prepares piece agent or capsule or drop pill.
A kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that pharmaceutical composition and controlling that chemical drugs or Chinese medicine form Treat esophageal cancer medicine.
The preparation method of a kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Herba Oberoniae iridifoliae 120-160 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 80-100 weight portion 7,4',4'''-Trimethylamentoflavone 20-30 weight portion Herba mazi stachydifolii 60-80 weight portion Adinandra millettii 40-70 weight portion；
Preparation method:
(1) Herba Oberoniae iridifoliae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), 7,4',4'''-Trimethylamentoflavone, Herba mazi stachydifolii, Adinandra millettii are taken by crude drug proportioning, mixing, use weight percent Specific concentration 17% ethanol, as solvent, extracts at 44 DEG C of warm macerating, and extraction time is 2 times, and each extraction time is 0.3 hour, every time Solvent load is 50 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into relatively Density 1.05, filters, and medicinal liquid passes through NKA-II macroporous adsorptive resins, first washes with water, then by weight percent concentration 55.5% Ethanol solution eluting NKA-II macroporous adsorptive resins, collects weight percent concentration 55.5% ethanol elution, reclaims ethanol, Concentrate drying, obtains extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 72.5% ethanol as solvent, heating and refluxing extraction 10 times, every time Extraction time is 0.4 hour, and each solvent load is 22 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, extracting solution B Reclaiming ethanol, be concentrated into relative density 1.09, filter, medicinal liquid passes through FU-02 macroporous adsorptive resins, first washes with water, then uses Weight percent concentration 57% ethanol solution eluting FU-02 macroporous adsorptive resins, collects weight percent concentration 57% ethanol and washes De-liquid, reclaims ethanol, concentrate drying, obtains extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Herba Oberoniae iridifoliae 140 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 90 weight portion 7,4',4'''-Trimethylamentoflavone 25 weight portion Herba mazi stachydifolii 70 weight portion Adinandra millettii 50 weight portion；
Preparation method:
(1) Herba Oberoniae iridifoliae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), 7,4',4'''-Trimethylamentoflavone, Herba mazi stachydifolii, Adinandra millettii are taken by crude drug proportioning, mixing, use weight percent Specific concentration 17% ethanol, as solvent, extracts at 44 DEG C of warm macerating, and extraction time is 2 times, and each extraction time is 0.3 hour, every time Solvent load is 50 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into relatively Density 1.05, filters, and medicinal liquid passes through NKA-II macroporous adsorptive resins, first washes with water, then by weight percent concentration 55.5% Ethanol solution eluting NKA-II macroporous adsorptive resins, collects weight percent concentration 55.5% ethanol elution, reclaims ethanol, Concentrate drying, obtains extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 72.5% ethanol as solvent, heating and refluxing extraction 10 times, every time Extraction time is 0.4 hour, and each solvent load is 22 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, extracting solution B Reclaiming ethanol, be concentrated into relative density 1.09, filter, medicinal liquid passes through FU-02 macroporous adsorptive resins, first washes with water, then uses Weight percent concentration 57% ethanol solution eluting FU-02 macroporous adsorptive resins, collects weight percent concentration 57% ethanol and washes De-liquid, reclaims ethanol, concentrate drying, obtains extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that pharmaceutical composition can use preparation The conventional method learned is prepared as tablet or capsule or drop pill.
A kind of preparation method of the pharmaceutical composition treating esophageal carcinoma, it is characterised in that pharmaceutical composition and chemical drugs or in Medicine composition treatment esophageal cancer medicine.
Medicine composite for curing esophageal carcinoma is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of esophageal carcinoma and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of esophageal carcinoma be: Herba Oberoniae iridifoliae 140g Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 90g parasol pine Bisflavone 25g Herba mazi stachydifolii 70g Adinandra millettii 50g；
Preparation method:
(1) Herba Oberoniae iridifoliae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), 7,4',4'''-Trimethylamentoflavone, Herba mazi stachydifolii, Adinandra millettii are taken by crude drug proportioning, mixing, use weight percent Specific concentration 17% ethanol, as solvent, extracts at 44 DEG C of warm macerating, and extraction time is 2 times, and each extraction time is 0.3 hour, every time Solvent load is 50 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into relatively Density 1.05, filters, and medicinal liquid passes through NKA-II macroporous adsorptive resins, first washes with water, then by weight percent concentration 55.5% Ethanol solution eluting NKA-II macroporous adsorptive resins, collects weight percent concentration 55.5% ethanol elution, reclaims ethanol, Concentrate drying, obtains extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 72.5% ethanol as solvent, heating and refluxing extraction 10 times, every time Extraction time is 0.4 hour, and each solvent load is 22 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, extracting solution B Reclaiming ethanol, be concentrated into relative density 1.09, filter, medicinal liquid passes through FU-02 macroporous adsorptive resins, first washes with water, then uses Weight percent concentration 57% ethanol solution eluting FU-02 macroporous adsorptive resins, collects weight percent concentration 57% ethanol and washes De-liquid, reclaims ethanol, concentrate drying, obtains extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of esophageal carcinoma and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of esophageal carcinoma be: Herba Oberoniae iridifoliae 160g Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 80g parasol pine Bisflavone 30g Herba mazi stachydifolii 60g Adinandra millettii 70g；
Preparation method:
(1) Herba Oberoniae iridifoliae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), 7,4',4'''-Trimethylamentoflavone, Herba mazi stachydifolii, Adinandra millettii are taken by crude drug proportioning, mixing, use weight percent Specific concentration 17% ethanol, as solvent, extracts at 44 DEG C of warm macerating, and extraction time is 2 times, and each extraction time is 0.3 hour, every time Solvent load is 50 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into relatively Density 1.05, filters, and medicinal liquid passes through NKA-II macroporous adsorptive resins, first washes with water, then by weight percent concentration 55.5% Ethanol solution eluting NKA-II macroporous adsorptive resins, collects weight percent concentration 55.5% ethanol elution, reclaims ethanol, Concentrate drying, obtains extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 72.5% ethanol as solvent, heating and refluxing extraction 10 times, every time Extraction time is 0.4 hour, and each solvent load is 22 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, extracting solution B Reclaiming ethanol, be concentrated into relative density 1.09, filter, medicinal liquid passes through FU-02 macroporous adsorptive resins, first washes with water, then uses Weight percent concentration 57% ethanol solution eluting FU-02 macroporous adsorptive resins, collects weight percent concentration 57% ethanol and washes De-liquid, reclaims ethanol, concentrate drying, obtains extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of esophageal carcinoma and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of esophageal carcinoma be: Herba Oberoniae iridifoliae 120g Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 100g parasol pine Bisflavone 20g Herba mazi stachydifolii 80g Adinandra millettii 40g；
Preparation method:
(1) Herba Oberoniae iridifoliae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), 7,4',4'''-Trimethylamentoflavone, Herba mazi stachydifolii, Adinandra millettii are taken by crude drug proportioning, mixing, use weight percent Specific concentration 17% ethanol, as solvent, extracts at 44 DEG C of warm macerating, and extraction time is 2 times, and each extraction time is 0.3 hour, every time Solvent load is 50 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into relatively Density 1.05, filters, and medicinal liquid passes through NKA-II macroporous adsorptive resins, first washes with water, then by weight percent concentration 55.5% Ethanol solution eluting NKA-II macroporous adsorptive resins, collects weight percent concentration 55.5% ethanol elution, reclaims ethanol, Concentrate drying, obtains extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 72.5% ethanol as solvent, heating and refluxing extraction 10 times, every time Extraction time is 0.4 hour, and each solvent load is 22 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, extracting solution B Reclaiming ethanol, be concentrated into relative density 1.09, filter, medicinal liquid passes through FU-02 macroporous adsorptive resins, first washes with water, then uses Weight percent concentration 57% ethanol solution eluting FU-02 macroporous adsorptive resins, collects weight percent concentration 57% ethanol and washes De-liquid, reclaims ethanol, concentrate drying, obtains extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 357g, adds starch 222g, mixing, pelletizes, be dried, add microcrystalline Cellulose 109g, stearic Acid magnesium 8.5g, mixing, it is pressed into 1400, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 234g, adds starch 256g, mixing, pelletizes, be dried, granulate, add appropriate stearic acid Magnesium, mixing, encapsulated 1100, obtain medicament composition capsule.
Embodiment 6: the preparation of drop pill
Weigh polyethylene glycol 6000 250g water-bath (80 DEG C) heating and boil molten, add embodiment 3 pharmaceutical composition 13.2g, fully Stirring, with liquid paraffin as coolant, put in glass tubing (4*80cm), chilling temperature is 7 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.4cm away from liquid level, drips fast with 65 every point as optimum condition, blots the cold of drop pill surface with cotton Solidifying agent, obtains medicament composition dropping pills.
Experimental example 1: the experimental study for the treatment of esophageal carcinoma
1 data and method
1.1 case selection
Collect middle and advanced stage esophageal cancer patients 40 example that should not perform the operation or be reluctant in April, 2010 in May, 2011 to perform the operation, mean age 60.8 years old, Ka Shi marked complete 60 points.All cases are through esophagoscopy, and are diagnosed as through proved by pathology: squamous cell carcinoma.Utilize The table of random numbers is randomly divided into observation group 20 example, matched group 20 example.Two groups at aspects such as case load, sex, age, Clinical symptoms, No difference of science of statistics (P > 0.05), routine blood test during treatment, Liver and kidney function are normal, without chemotherapy contraindication, two groups have compare comparable Property.
1.2 dosage regimen
Matched group gives conventional therapy, DCF chemotherapy regimen: the 1-5 days, and calcium folinate (ClFecuvooirn) 200mz/ vein drips Note 2 hours；The 1-5 days, fluorouracil (5-FU) 500mg/m2Intravenous drip；Docetaxel 75mg/m2Intravenous drip l hour, uses First 1 day of docetaxel, the same day and latter 1 day oral dexamethasone 4.5mg, 2 times/day, the 1-3 days, cisplatin 30mg/m2Vein drips Note；Every 3 weeks is a cycle, is used in conjunction 2 cycles.Observation group, on the basis of conventional chemotherapy, adds pharmaceutical composition (embodiment 1 Pharmaceutical composition lot number 20100220) treatment: oral, a 1.5g, 3 times on the one, 30 days be a course for the treatment of.
1.3 observation index
1. short term effect: clinical efficacy is divided into four grades according to the relevant judgment criteria of WHO entity tumor: CR is (the most slow Solve), PR (part alleviate), SD (stablizing) and PD (progress), effective percentage=(CR+PR+SD)/(CR+PR+SD+PD) × 100%；② Late result: the survival rate of 1,2,3 years after treatment；3. untoward reaction: index scale according to the anticancer toxic reaction of WHO, point For I-VI level.
1.4 statistical procedures
Enumeration data compares employing X 2 test.For difference, there is statistical significance with P < 0.05.
2 results
2.1 short term effect
Two groups of short term effects are shown in Table 1, and observation group's effective percentage is apparently higher than comparison (single chemotherapy) group (P ＜ 0.05).Pharmaceutical composition Compare single chemotherapy and can significantly improve patient's effective percentage (P < 005).
1 liang of table group short term effect compares
Group Number of cases CR PR SD PD Effective percentage
Observation group 20 5 9 5 1 95.0%*
Matched group 20 3 5 7 5 75.0%
Note: compare * P < 0.05 with matched group.
2.2 late result
2 liang of table group late result compares
After treatment terminates, the survival rate observation group more statistically significant than matched group difference (P < 0.05) (table 2) of 1,2,3 year.Knot Fruit display, pharmaceutical composition is compared single chemotherapy and is remarkably improved survival.
2.3 untoward reaction
(example) is compared in the group untoward reaction of 3 liang of table
The incidence rate that observation group's digestive tract reaction, leukopenia, platelet decline is respectively less than matched group, I degree digestive tract reaction, Two groups are compared and have significant difference (P < 0.05).

Claims (8)

1. the pharmaceutical composition treating esophageal carcinoma, it is characterised in that make composition and the weight of the crude drug of this pharmaceutical composition Amount part is:
Herba Oberoniae iridifoliae 120-160 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 80-100 weight portion 7,4',4'''-Trimethylamentoflavone 20-30 weight portion Herba mazi stachydifolii 60- 80 weight portion Adinandra millettii 40-70 weight portions.
A kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that make this pharmaceutical composition The composition of crude drug and weight portion be:
Herba Oberoniae iridifoliae 140 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 90 weight portion 7,4',4'''-Trimethylamentoflavone 25 weight portion Herba mazi stachydifolii 70 weight portion Adinandra millettii 50 weight portions.
A kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that pharmaceutical composition can be adopted It is prepared as tablet or capsule or drop pill by the conventional method of galenic pharmacy.
A kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that pharmaceutical composition and chemistry Medicine or the treatment esophageal cancer medicine of Chinese medicine composition.
5. the preparation method of the pharmaceutical composition treating esophageal carcinoma, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: Herba Oberoniae iridifoliae 120-160 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 80-100 weight portion 7,4',4'''-Trimethylamentoflavone 20-30 weight portion Herba mazi stachydifolii 60-80 weight portion Adinandra millettii 40-70 weight portion；
Preparation method:
(1) Herba Oberoniae iridifoliae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), 7,4',4'''-Trimethylamentoflavone, Herba mazi stachydifolii, Adinandra millettii are taken by crude drug proportioning, mixing, use weight percent Specific concentration 17% ethanol, as solvent, extracts at 44 DEG C of warm macerating, and extraction time is 2 times, and each extraction time is 0.3 hour, every time Solvent load is 50 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into relatively Density 1.05, filters, and medicinal liquid passes through NKA-II macroporous adsorptive resins, first washes with water, then by weight percent concentration 55.5% Ethanol solution eluting NKA-II macroporous adsorptive resins, collects weight percent concentration 55.5% ethanol elution, reclaims ethanol, Concentrate drying, obtains extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 72.5% ethanol as solvent, heating and refluxing extraction 10 times, every time Extraction time is 0.4 hour, and each solvent load is 22 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, extracting solution B Reclaiming ethanol, be concentrated into relative density 1.09, filter, medicinal liquid passes through FU-02 macroporous adsorptive resins, first washes with water, then uses Weight percent concentration 57% ethanol solution eluting FU-02 macroporous adsorptive resins, collects weight percent concentration 57% ethanol and washes De-liquid, reclaims ethanol, concentrate drying, obtains extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that by as follows Prepared by step:
The composition of crude drug and weight portion be: Herba Oberoniae iridifoliae 140 weight portion Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae) 90 weight portion 7,4',4'''-Trimethylamentoflavone 25 weight portion Herba mazi stachydifolii 70 weight portion Adinandra millettii 50 weight portion；
Preparation method:
(1) Herba Oberoniae iridifoliae, Rhizoma Calystegiae Hederaceae (Herba Calystegiae Hederaceae), 7,4',4'''-Trimethylamentoflavone, Herba mazi stachydifolii, Adinandra millettii are taken by crude drug proportioning, mixing, use weight percent Specific concentration 17% ethanol, as solvent, extracts at 44 DEG C of warm macerating, and extraction time is 2 times, and each extraction time is 0.3 hour, every time Solvent load is 50 times of crude drug gross weight, filters, obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, is concentrated into relatively Density 1.05, filters, and medicinal liquid passes through NKA-II macroporous adsorptive resins, first washes with water, then by weight percent concentration 55.5% Ethanol solution eluting NKA-II macroporous adsorptive resins, collects weight percent concentration 55.5% ethanol elution, reclaims ethanol, Concentrate drying, obtains extract A；
(2) step (1) medicinal residues A is taken, with weight percent concentration 72.5% ethanol as solvent, heating and refluxing extraction 10 times, every time Extraction time is 0.4 hour, and each solvent load is 22 times of medicinal residues A weight, filters, obtains medicinal residues B and extracting solution B, extracting solution B Reclaiming ethanol, be concentrated into relative density 1.09, filter, medicinal liquid passes through FU-02 macroporous adsorptive resins, first washes with water, then uses Weight percent concentration 57% ethanol solution eluting FU-02 macroporous adsorptive resins, collects weight percent concentration 57% ethanol and washes De-liquid, reclaims ethanol, concentrate drying, obtains extract B；
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that medicine group Compound can use the conventional method of galenic pharmacy to be prepared as tablet or capsule or drop pill.
The preparation method of a kind of pharmaceutical composition treating esophageal carcinoma, it is characterised in that medicine group Compound and chemical drugs or Chinese medicine composition treatment esophageal cancer medicine.
CN201610501397.1A 2016-06-30 2016-06-30 Medicine composition for treating esophagus cancer Withdrawn CN105998697A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610501397.1A CN105998697A (en) 2016-06-30 2016-06-30 Medicine composition for treating esophagus cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610501397.1A CN105998697A (en) 2016-06-30 2016-06-30 Medicine composition for treating esophagus cancer

Publications (1)

Publication Number Publication Date
CN105998697A true CN105998697A (en) 2016-10-12

Family

ID=57104530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610501397.1A Withdrawn CN105998697A (en) 2016-06-30 2016-06-30 Medicine composition for treating esophagus cancer

Country Status (1)

Country Link
CN (1) CN105998697A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189210A1 (en) * 2017-04-12 2018-10-18 Institut Gustave Roussy Compounds, composition and uses thereof for treating cancer
CN117815223A (en) * 2024-03-06 2024-04-05 北京市肿瘤防治研究所 Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189210A1 (en) * 2017-04-12 2018-10-18 Institut Gustave Roussy Compounds, composition and uses thereof for treating cancer
IL269769A (en) * 2017-04-12 2019-11-28 Roussy Inst Gustave Compounds, composition and uses thereof for treating cancer
KR20190138840A (en) * 2017-04-12 2019-12-16 인스티튜트 구스타브 루시 Compounds, compositions and uses thereof for treating cancer
CN110891944A (en) * 2017-04-12 2020-03-17 法国古士塔柏罗斯学院 Compounds, compositions and uses thereof for the treatment of cancer
JP2020516612A (en) * 2017-04-12 2020-06-11 アンスティテュ・ギュスターヴ・ルシー Compounds, compositions and uses thereof for the treatment of cancer
US11110105B2 (en) 2017-04-12 2021-09-07 Institut Gustave Roussy Compounds, composition and uses thereof for treating cancer
AU2018251949B2 (en) * 2017-04-12 2021-10-07 Centre National De La Recherche Scientifique Compounds, composition and uses thereof for treating cancer
JP7044803B2 (en) 2017-04-12 2022-03-30 アンスティテュ・ギュスターヴ・ルシー Compounds, compositions and uses thereof for the treatment of cancer
CN110891944B (en) * 2017-04-12 2023-05-05 法国古士塔柏罗斯学院 Compounds, compositions and uses thereof for the treatment of cancer
KR102600728B1 (en) * 2017-04-12 2023-11-09 인스티튜트 구스타브 루시 Compounds, compositions and uses thereof for treating cancer
CN117815223A (en) * 2024-03-06 2024-04-05 北京市肿瘤防治研究所 Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma

Similar Documents

Publication Publication Date Title
CN103893722B (en) A kind of Chinese medicine composition and its preparation method treating sunburn
CN105998697A (en) Medicine composition for treating esophagus cancer
CN118434431A (en) Traditional Chinese medicine composition and preparation method and application thereof
CN105535265A (en) Pharmaceutical composition for treating pancreatic cancer
CN116115687B (en) Traditional Chinese medicine composition for gout and preparation method and application thereof
CN106109927A (en) A kind of pharmaceutical composition treating chloasma and preparation method thereof
CN107661392A (en) A kind of Chinese medicine compound prescription for treating cancer of the esophagus and preparation method thereof
Ye et al. Medicinal Gymnosperms of Ginkgoaceae, Pinaceae, Cupressaceae, Taxodiaceae, and Podocarpaceae
CN106581357A (en) Pharmaceutical composition for treatment of recurrent oral ulcer
CN105560694A (en) Medicine composition for treating diabetic nephropathy and preparation method thereof
CN106074736A (en) A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof
CN106109551A (en) A kind of pharmaceutical composition preventing and treating chloasma
CN105497145A (en) Medicine composition for preventing and curing lung cancer and preparation method thereof
CN105287863A (en) Pharmaceutical composition for curing DN (Diabetic Nephropathy) and preparation method of pharmaceutical composition
Ye et al. Medicinal Angiosperms of Ranunculaceae, Nymphaeaceae, and Berberidaceae
CN105497251A (en) Medicine composition for treating functional dyspepsia
CN117224598A (en) Traditional Chinese medicine preparation for treating insomnia and preparation method thereof
CN105641170A (en) Medicine composition for treating esophageal cancer
CN106581094A (en) Pharmaceutical composition for treating acne
CN106038754A (en) Medicine composition for preventing and treating cervical cancer and preparation method thereof
CN105287864A (en) Medicinal composition for treating constipation caused by malignant tumors
CN106728474A (en) Treat the pharmaceutical composition of thyroid disease
CN105998332A (en) Medicine composition for treating advanced breast cancer
CN106692578A (en) Pharmaceutical composition for preventing and treating oral ulcer and preparation method of pharmaceutical composition
CN106668543A (en) Medicinal composition for preventing and treating cervicitis and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20161012